Mutations in CHEK2 Associated with Prostate Cancer Risk  by Dong, Xiangyang et al.
Am. J. Hum. Genet. 72:270–280, 2003
270
Mutations in CHEK2 Associated with Prostate Cancer Risk
Xiangyang Dong,1,* Liang Wang,1,* Ken Taniguchi,1 Xianshu Wang,1 Julie M. Cunningham,1
Shannon K. McDonnell,2 Chiping Qian,1 Angela F. Marks,1 Susan L. Slager,2 Brett J. Peterson,2
David I. Smith,1 John C. Cheville,1 Michael L. Blute,3 Steve J. Jacobsen,2 Daniel J. Schaid,2
Donald J. Tindall,3 Stephen N. Thibodeau,1 and Wanguo Liu1
1Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, and Departments of 2Health Sciences Research and
3Urology, Mayo Clinic/Mayo Medical School, Rochester, MN
The DNA-damage–signaling pathway has been implicated in all human cancers. However, the genetic defects and
the mechanisms of this pathway in prostate carcinogenesis remain poorly understood. In this study, we analyzed
CHEK2, the upstream regulator of p53 in the DNA-damage–signaling pathway, in several groups of patients with
prostate cancer. A total of 28 (4.8%) germline CHEK2 mutations (16 of which were unique) were found among
578 patients. Additional screening for CHEK2 mutations in 149 families with familial prostate cancer revealed 11
mutations (5 unique) in nine families. These mutations included two frameshift and three missense mutations.
Importantly, 16 of 18 unique CHEK2 mutations identified in both sporadic and familial cases were not detected
among 423 unaffected men, suggesting a pathological effect of CHEK2 mutations in prostate cancer development.
Analyses of the two frameshift mutations in Epstein Barr virus–transformed cell lines, using reverse-transcriptase
polymerase chain reaction and western blot analysis, revealed abnormal splicing for one mutation and dramatic
reduction of CHEK2 protein levels in both cases. Overall, our data suggest that mutations inCHEK2may contribute
to prostate cancer risk and that the DNA-damage–signaling pathway may play an important role in the development
of prostate cancer.
Introduction
Genetic components contributing to prostate cancer
(MIM 300200) have been difficult to identify, largely
because of the complexity of this disease and the pres-
ence of phenocopies in high-risk families. Current ge-
netic studies, using linkage analysis of “high-risk fami-
lies” followed by positional cloning approaches, have
identified more than six susceptibility loci (Ostrander
and Stanford 2000). Only two studies have shown any
success with the cloning of candidate susceptibility genes
from these regions: HPC1 (MIM 601518) and HPC2/
ELAC2 (MIM 605367), localized to chromosomes 1q
and 17p, respectively (Tavtigian et al. 2001; Carpten et
al. 2002). However, follow-up studies forHPC2/ELAC2
have failed to replicate the original findings (Wang et al.
2001; Xu et al. 2001) or have suggested only a limited
role in hereditary prostate cancer (Rebbeck et al. 2000;
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Wang et al. 2001). Since prostate cancer is heterogeneous
in nature, and because of the difficulty in identifying
highly penetrant susceptibility genes, it may be that the
pathogenesis of the disease is related, at least in part, to
genomic mutations in multiple low-penetrance genes.Al-
though less penetrant, such genes might play an impor-
tant role at a population level.
Genomic instability is a common feature of many hu-
man cancers (Hoeijmakers 2001). The DNA-damage–
signaling pathway plays a critical role in maintaining
genomic stability in response to a variety of DNA-dam-
aging events (Khanna and Jackson 2001). Disruption of
this pathway has been shown to be pivotal in cancer
development, since several proteins involved in this path-
way (such as BRCA1 [MIM 113705], TP53 [MIM
191170], and ATM [MIM 208900]) are frequently mu-
tated in human cancers and in several heritable cancer-
prone syndromes, such as Li-Fraumeni syndrome (LFS
[MIM151623]) and ataxia telangiectasia (MIM208900)
(Malkin et al. 1990; Miki et al. 1994; Savitsky et al.
1995). Evidence that the DNA-damage–signaling path-
way is also important in prostate cancer development
comes from several studies. Adenovirus-mediated anti-
sense ATM gene transfer has been shown to sensitize
prostate cancer cells to radiation (Fan et al. 2000), and
mutation in p53 is associated with amplification of the
androgen receptor (MIM 313700) gene in prostate can-
cer (Koivisto and Rantala 1999). In addition, a low fre-
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quency of germline mutations in the breast cancer pre-
disposition genes BRCA1 and BRCA2 (MIM 600185)
has been identified in familial prostate cancer (Gayther
et al. 2000). Moreover, the male mutation carriers in
these families had been shown to have a 3.3-fold in-
creased risk for prostate cancer, relative to the general
population (Ford et al. 1994). Cumulatively, these data
support the notion that the integrity of the DNA-dam-
age–signaling pathway is essential for the prevention of
prostate cancer. Since mutations in TP53, the key regu-
lator of the DNA-damage–signaling pathway, are infre-
quent in prostate cancer but common in all other cancer
types, we hypothesized that other components in this
pathway could be mutation targets in prostate cancer.
CHEK2 (MIM 604373) is a mammalian homologue
of the Saccharomyces cerevisiae Rad53 and Schizosac-
charomyces pombe Cds1, both of which are involved
in the DNA-damage–signaling pathway (Paulovich and
Hartwell 1995; Sanchez et al. 1996; Boddy et al. 1998).
CHEK2 is phosphorylated in response to various DNA-
damage agents in an ATM-dependent fashion (Matsuoka
et al. 1998). Activated CHEK2, along with other DNA-
damage–activated protein kinases, stabilizes TP53 or en-
hances degradation of Cdc25A (MIM116974) in the cell-
cycle checkpoint control (Matsuoka et al. 1998; Hirao
et al. 2000; Falck et al. 2001), through coordination of
DNA repair, cell-cycle progression, and apoptosis (Cas-
pari 2000; Bulavin et al. 2001). Recently, heterozygous
germline mutations in the CHEK2 gene have been iden-
tified in patients with LFS, a highly penetrant familial
cancer phenotype usually associated with inherited mu-
tations in TP53 (Bell et al. 1999). One of the CHEK2
germline mutations (1100delC) identified in LFSwas also
identified in 5.1% of noncarriers of BRCA1 or BRCA2
mutations in families with breast cancer, suggesting its
involvement in familial breast cancer, as well (Meijers-
Heijboer et al. 2002). Subsequently, somaticCHEK2mu-
tations were also found in a subset of the primary tumors
of LFS, such as sarcoma, breast cancer, and brain tumors,
but were rare in other tumors (Allinen et al. 2001; Miller
et al. 2002).
In this study, we examined DNA from patients with
both sporadic and familial prostate cancers for muta-
tions in CHEK2. We compared the frequency of the
CHEK2 mutations in these two prostate-cancer groups
with that in an unaffected control group, to determine
whether defects in CHEK2 play a role in the develop-
ment of prostate cancer.
Material and Methods
Ascertainment of Patients with Prostate Cancer
Tissue.—Two separate sets of primary prostate tumor
samples were collected at the Mayo Clinic and used in
this study. The first set of tumor tissues ( ) wasnp 84
unselected and was collected between 1997 and 1998.
The second set ( ) was selected for young age atnp 92
diagnosis (!59 years) and was collected between 2000
and 2001. For these patients, neither family history in-
formation nor blood was available.
Blood.—For a third group, blood was collected from
patients with prostate cancer ( ) with no familynp 400
history of prostate cancer. These patients with sporadic
prostate cancer were collected at the Mayo Clinic and
were selected from respondents to a family history sur-
vey who reported no family history of prostate cancer
(Wang et al. 2001). They were matched by year of di-
agnosis, age at diagnosis, and number of brothers in the
familial group, which is described below. All but 11 of
these men were treated surgically for their prostate
cancer.
Familial Prostate Cancer Ascertainment
Families with familial clustering of prostate cancer
were ascertained as described elsewhere (Berry et al.
2000). These families have occurrence of prostate cancer
in a minimum of three men over at least two generations.
Blood was collected from as many family members as
possible. All men with prostate cancer who contributed
a blood specimen had their cancers verified by review
of medical records and pathologic confirmation. One
family had Hispanic ancestry, and the remainder were
white. Two affected members (the proband and one ran-
domly selected affected man from the family) from each
of 149 families were initially selected for mutation anal-
ysis. When mutations were identified, the other available
family members were also screened for the specific
mutation.
Unaffected Control Individuals
From a sampling frame of the local population, pro-
vided by the Rochester Epidemiology Project (Melton
1996), 475 men were randomly selected for a clinical
urologic examination (Oesterling et al. 1993). This exam
included digital rectal examination (DRE) and transrec-
tal ultrasound (TRUS) of the prostate, abdominal ultra-
sound for post-void residual urine volume, serum pros-
tate-specific antigen (PSA) and creatinine measurement,
focused urologic physical examination, and cryopres-
ervation of serum for subsequent sex-hormone assays.
Any patient with an abnormal DRE, elevated serum PSA
level, or suspicious lesion on TRUS was evaluated for
prostatic malignancy. If the DRE and TRUS were un-
remarkable and the serum PSA level was elevated (14.0
ng/ml), a sextant biopsy (three cores from each side) of
the prostate was performed. An abnormal DRE or TRUS
result, regardless of the serum PSA level, prompted a
biopsy of the area in question. In addition, a sextant
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biopsy of the remaining prostate was performed. Those
men who were found to be without prostate cancer on
the basis of this extensive work-up, at baseline or at any
of the follow-up exams through 1994, were used for the
control population ( ). To make up for studynp 372
attrition, the sample was augmented with random sam-
ples from individuals in the population who were sub-
jected to an identical workup ( ), resulting in anp 138
total sample of 510 men without evidence of prostate
cancer (Roberts et al. 2000). Three hundred and thirty-
one of these individuals gave informed consent to par-
ticipate in this particular study. The second group of
normal control DNA samples was obtained from 92men
participating in an ongoing NCI prostate cancer chemo-
prevention trial, all of whom were free of evidence of
prostate cancer at the time blood was collected, on the
basis of DRE and PSA (PSA level !3 ng/ml). The mean
age for the 86 men with age data available was 65 years
(range 57.6–75.9 years). These two groups of control
individuals were combined for the analysis. This study
was approved by the Mayo Clinic institutional review
board.
Genomic PCR and Mutation Analyses
DNA and RNA isolation from blood, tumor tissues,
and cell lines were performed following the manufac-
turer’s protocol (QIAGEN). Thirteen pairs of intronic
primers covering 14 exons of the CHEK2 gene (Gen-
Bank accession number XM_009898) were designed
(available upon request). Primers used for amplification
of exons 10–14 were particularly designed so that either
one or both primers for each set of primers had a base
mismatch in the most 3′ nucleotide, compared with se-
quences from nonfunctional copies of CHEK2. The
primers thus preferentially amplified the functional
CHEK2 on chromosome 22 rather than nonfunctional
copies elsewhere in the genome. PCR amplification was
performed in a volume of 12.5 ml containing 25 ng of
genomic DNA, each primer at 0.2 mM, each dNTP at
0.2 mM, 2.0 mM MgCl2, 0.5 U of Taq polymerase
(AmpliTaq Gold, Perkin Elmer), and 1# buffer provided
by the manufacturer. Denaturing high-performance liq-
uid chromatography (DHPLC) analyses and direct se-
quencing of the PCR products were performed as de-
scribed elsewhere (Liu et al. 1997).
RT-PCR
Lymphoblastoid cell lines from the proband of each
family were established on the basis of standard proce-
dures. Lymphocytes from peripheral blood were trans-
formed with Epstein-Barr virus (EBV) and were cultured
in RPMI-1640 medium containing 10% fetal bovine se-
rum. All transformed cells were frozen in liquid nitrogen
for future use. CHEK2 germline mutations in these cell
lines were confirmed by direct sequencing of genomic
DNA. The two pairs of primers used for RT-PCR analysis
of the mutations are as follows: CHK2F2 (5′-AAAAGAA-
CAGATAAATACCGAACAT-3′) and CHKR2 (5′-TCTG-
CCTCTCTTGCTGAACC-3′), covering the mutations
T470C, G715A, and A751T; and CHK2F3 (5′-AATTGA-
TGGAAGGGGGAGAGCTGT-3′) and CHK2R3 (5′-T-
AGGTGGGGGTTCCACATAAGGT-3′), covering the
1100delC mutation. For RT-PCR analysis of the abnor-
mal splicing products in the IVS21GrA mutant, one
pair of exonic primers covering nucleotides 367 (in exon
2) to 564 (in exon 3) were designed (forward, 5′-TATTG-
CTTTGATGAACCACTGC-3′; reverse, 5′-TTCAGAA-
TTGTTATTCAAAGGAC-3′). RT-PCR products were
cloned into pGEM-T easy vector, according to the man-
ufacturer’s protocol (Promega). The abnormal splicing
products were detected by DHPLC and were then directly
sequenced.
Western Blot Analysis
CHEK2 proteins in the cell lines with CHEK2 mu-
tations were analyzed by western blot analysis. In brief,
total protein from each cell line was harvested, dena-
tured in Laemnli buffer (Bio-Rad), and separated on 8%
polyacrylamide gels with prestained protein Benchmark
(Gibco/BRL). After being transferred onto Hybond ECL
nitrocellulose membrane (Amersham Pharmacia Bio-
tech), CHEK2 protein was visualized with rabbit poly-
clonal anti-CHEK2 antibody raised against N-terminal
residues of human CHEK2 (kindly provided by Dr. J.
Chen) by the ECL Western Blotting System (Amersham
Pharmacia Biotech). The mouse monoclonal anti-b-actin
antibody (clone AC-15, Sigma) was used as an internal
control.
Statistical Methods
The frequencies of mutation carriers were compared
among different groups, through use of Armitage’s test
for trend. For statistical comparisons of patients with
familial disease versus control subjects, a test for trend
in the number of variant alleles, analogous to Armitage’s
test for trend in proportions (Sasieni 1997) but with the
appropriate variance to account for the correlated family
data, was used (Slager and Schaid 2001).
Results
CHEK2 Mutation Screening
In this study, we screened the CHEK2 gene for mu-
tations in several groups of men with prostate cancer.
For the first two groups, only tissue (tumor and matched
normal) was available for study (clinic tumors 1 and 2
in table 1). In the 178 patients with available tissue, 13
CHEK2 mutations were identified (table 1; fig. 1). Nine
Table 1
CHK2 Germline Mutations Identified in Men with Prostate Cancer and in Unaffected Control Individuals
Mutation Number Mutation
Amino Acid
Change Exon Domain
Clinic
Tumors 1
( )anp 84
Clinic
Tumors 2
( )bnp 94
Individuals
with Sporadic
Prostate Cancer
( )cnp 400
Individuals
with Familial
Prostate Cancer
( )dnp 298
Unaffected Men
( )enp 423
1 G190A Glu64Lys 1 S/TQ-rich 1 0 1 0 0
2 245del15 bp del DQEPE 1 S/TQ-rich 0 0 1 0 0
3 G434C Arg145Pro 2 FHA 0 0 1 0 0
4 IVS21GrA Frameshift 2 FHA 0 0 0 1 0
5 T470C Ile157Thr 3 FHA 1 0 6 7 5
6 G499A Gly167Arg 3 FHA 0 0 1 0 0
7 C538T Arg180Cys 3 Unknown 0 2 0 0 1
8 G539A Arg180His 3 Unknown 0 0 1 0 0
9 C541T Arg181Cys 3 Unknown 1 0 0 0 0
10 G542A Arg181His 3 Unknown 0 0 1 0 0
11 G715T Glu239Stop 5 Kinase 0 0 1 0 0
12 G715A Glu239Lys 5 Kinase 1 0 0 1 0
13 A751T Ile251Phe 5 Kinase 0 0 0 1 0
14 G954A Arg318His 8 Kinase 0 1 0 0 0
15 A967C Thr323Pro 8 Kinase 1 0 0 0 0
16 A980G Tyr327Cys 8 Kinase 0 0 1 0 0
17 1100delC Frameshift 10 Kinase 3 1 1 1 0
18 C1427A Thr476Lys 12 Kinase 1 0 0 0 0
Total 9 (10.7%) 4 (4.3%) 15 (3.75%) 11 (3.7%) 6 (1.4%)
P value (Ile157Thr included)f !.0001 .07 .03 .08
P value (Ile157Thr excluded)g !.0001 .0003 .008 .11
a Unselected prostate-cancer tumor samples collected in 1997 and 1998.
b Prostate-cancer tumor samples, with a younger age at onset (age !59 years), collected in 2000 and 2001.
c Blood samples from patients without a family history of prostate cancer.
d Two affected men from each of 149 families were screened.
e Population-based control group ( ) with a mean age at diagnosis of 53.4 years (range 42–83 years), an average PSA value of 0.9 (range 0.15–9.1), and normalnp 331
TRUS and DRE results, plus a group of unaffected men ( ) enrolled in an ongoing NCI prostate cancer chemoprevention trail, who were free of clinically evident prostatenp 92
cancer as assessed by DRE and PSA (!3).
f P values comparing each group with controls, using Armitage’s test for trend. Control data: 6 (1.4%) with mutation, 417 (98.6%) with no mutation.
g P values comparing each group with controls, using Armitage’s test for trend. Control data: 1 (0.2%) with mutation, 422 (99.8%) with no mutation.
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Figure 1 CHEK2 germline mutations in prostate cancers. A, Mutations found in the CHEK2 gene. “T” indicates the clinic or sporadic
prostate tumor samples (numbers as shown in table 1), and “F” indicates families with prostate cancer in which CHEK2 mutations were
identified (numbers as indicated in fig. 2). B, Sequence analysis shows the five CHEK2 germline mutations identified in families with familial
prostate cancer. DNA sequence analyses were performed on either genomic DNA (first four pairs of panels) or cDNA (right-most panels).
Sequences are presented in the 5′r3′ direction, and arrows mark the location of each mutation. The upper panels depict the regions from wild-
type alleles and the lower panels show the respective sequences with the mutations. All mutations were detected with genomic DNA and were
confirmed with cDNA.
(10.7%) were detected among the 84 unselected patients
with prostate cancer, and 4 (4.3%) were detected among
the 94 patients with early-onset cancer. These included
eight different missense mutations and 1-bp deletionmu-
tations at nucleotide 1100 (1100delC). All of the mu-
tations altered evolutionarily conserved amino acids,
with the exception of the Arg181Cys mutation in exon
3. These mutations were considered to most likely be
germline mutations, since they were present in both tu-
mor and matched normal prostate tissues. However,
since DNA from blood was not available for analysis,
there is a possibility that they may represent very early
somatic events. In an effort to address this concern,DNA
from blood leukocytes was obtained from an additional
400 patients with prostate cancer without a family his-
tory of prostate cancer. Fifteen CHEK2 mutations were
identified in this third group (3.75%) (table 1). Although
there are differences in the frequency of CHEK2 mu-
tations among the three prostate cancer groups, the over-
all incidence of CHEK2 mutations present in these pa-
tients (28/578, 4.8%) suggest that CHEK2 germline
mutations are likely to be associated with development
of a subset of prostate cancer.
To investigate whether the CHEK2 mutations are also
present in familial prostate cancer, we screened two af-
fected members from each of 149 families with familial
prostate cancer collected at the Mayo Clinic (Berry et
al. 2000). Five differentCHK2mutations in nine families
were identified (table 1; fig. 1). Three were missense mu-
tations—one in exon 3 (T470C, Ile157Thr) and two in
exon 5 (G715A, Glu239Lys and A751T, Ile251Phe). The
other two were frameshift mutations, including the
1100delC mutation and a splice-site mutation in intron
2 (IVS21GrA). All five mutations changed amino ac-
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ids in either the FHA (forkhead homology-associated)
or the kinase activation domain of CHK2, which have
previously been shown to be important for protein-pro-
tein interaction and phosphorylation of p53 in DNA-
damage–signaling (Durocher et al. 2000; Shieh et al.
2000; Li et al. 2002). The presence of these mutations
in such important functional domains further suggested
that these CHK2 mutations could be deleterious.
To evaluate the association between the CHEK2 mu-
tations and prostate cancer risk, we screened a group of
unaffected men ( ). This group was comprised ofnp 423
two individual sets (table 1). One set contained 331 pop-
ulation-based unaffected control men (Wang et al. 2001),
and the other was comprised of 92 control men free of
evidence of prostate cancer. Within this control group,
two different mutations among six individuals were de-
tected: Arg180Cys ( ) and Ile157Thr ( ) (tablenp 1 np 5
1). For the six unaffected men with CHEK2 alterations,
there was no evidence of disease at the time of blood
collection. However, the mean age of these individuals at
the time of collection was only 59.6 years (range 45.5–
67.0 years), much younger than 71 years, the mean age
at diagnosis of prostate cancer for whites in the United
States (Bell et al. 1999). Although it is possible that these
individuals may develop prostate cancer or other malig-
nancies occurring in LFS or LFS-like syndromes later in
life, it is also likely that the Ile157Thr alteration represents
a polymorphism rather than a causative mutation.
Among the mutations detected, the frequency of the
Ile157Thr mutation did not appear to differ between case
(1.6%) and control (1.18%) individuals. We therefore
tested the significance of ourmutation datawith andwith-
out this alteration. A global test using Fisher’s exact test
showed a significant difference among all of the groups
( ). When the Ile157Thr mutation was omitted,Pp .002
the P value was !.0001. Each of the four case groups was
then compared individually with the pooled control
groups. With all of the data included, only the first un-
selected group and the sporadic case group showed a
statistically significant increase in the frequency of
CHEK2 mutations, compared with the control group (ta-
ble 1). When the Ile157Thr mutation was excluded, each
of the three nonfamilial groups demonstrated statistically
significant increases ( , .0003, and .008, respec-P ! .0001
tively). In both analyses, the frequency of CHEK2 mu-
tations in the familial group was not statistically different
than the control group. When the mutations are broken
down into four different categories (1100delC, all trun-
cating mutations, all missense mutations, and all missense
mutations except Ile157Thr), the associations between the
mutations and prostate cancer risk are still significant,
with the exception of 1100delC. However, the numbers
within each category are too small to allow conclusions
to be drawn. The 1100delC mutation has been proposed
to confer a low penetrant risk associated with breast can-
cer risk. Whether it is also a risk factor for prostate cancer
or other cancers remains to be elucidated.
CHEK2 Mutations Present in Families with Familial
Prostate Cancer
To determine whether CHEK2 mutations cosegre-
gated with prostate cancer in the nine families (families
1–9 in fig. 2), we analyzed the DNA from all available
family members for CHEK2 mutations, including both
affected and unaffected individuals. Families 1, 3, 4, 5,
and 6 had the Ile157Thr mutation. This alteration was
present in all affected individuals in two of the five fam-
ilies (families 1 and 4). Family 1 had six prostate cancer
cases in two generations. The Ile157Thr mutation was
present in all three affected men, including two brothers
(individuals 12 and 13) and their cousin (individual 11),
and was absent from three unaffected male siblings (in-
dividuals 9, 10, and 14). Although not tested directly,
the proband’s father (individual 7) and paternal uncle
(individual 4) are also expected to be carriers of this
mutation, since both are affected and have affected sons
with a mutation. In family 4, all the individuals affected
with prostate cancer carried the Ile157Thr mutation.
However, three sisters also carried the mutation but had
no evidence of cancer.
Four families (families 2, 7, 8, 9) had mutations other
than Ile157Thr. Family 2 is a family with multiple can-
cers, including five prostate cancers, two breast cancers,
two uterine cancers, three skin cancers, one lung cancer,
one bladder cancer, and one lip cancer, in six males and
five females in three generations (fig. 2). The proband
harbors the 1100delC mutation. Analysis of the avail-
able DNA from three affected men and one unaffected
man of this family revealed the mutation in two affected
men but not in the unaffected brother. The proband’s
daughters, one of whom was diagnosed with breast can-
cer and two of whom were diagnosed with uterine can-
cer, were not available for study. In the other three fam-
ilies, the CHEK2 mutation was detected in only one of
the two affected brothers. Overall, analysis of CHEK2
mutations in available family members from all nine
families revealed that 17 of 25 (68%) affected men har-
bored CHEK2 mutations, whereas none of the unaf-
fected men ( ) carried the mutation (fig. 2).np 8
To test for cosegregation of CHEK2 mutations with
prostate cancer, we performed linkage analyses under
the assumption of an autosomal dominant model (Smith
et al. 1996) and no recombination between the under-
lying susceptibility locus with CHEK2. Although seven
of nine families showed evidence against cosegregation,
we could rule out only cosegregation with a highly pen-
etrant effect; we cannot rule out a weakly penetrant
effect with our data.
Figure 2 Segregation of CHEK2 mutations in nine families with prostate cancer (families 1–9). Where known, the individual’s age is
indicated to the right side of each cancer. A dot (●) is present at the lower right corner of the symbol if a blood sample was available and was
analyzed. An asterisk (*) to the right of the symbol indicates the presence of the CHEK2 mutation carriers in each family. The individual
indicated with a dot but without an asterisk has tested negative for CHEK2 mutation. Arrows (↗) indicate probands. Squares denote males;
circles denote females; completely blackened symbols denote patients with prostate cancer for whom pathology records were available; 3/4
blackened symbols denote patients with prostate cancer for whom records were unavailable; 1/2 blackened symbols denote patients with other
types of cancer; all symbols with a diagonal denote deceased individuals. The cancer type for each individual is shown underneath each symbol.
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Figure 3 Abnormal splicing and abnormal protein syntheses of the two CHEK2 frameshift mutations. A, Schematic representation of the
abnormal splice for the IVS21GrA mutant. A 4-bp insertion is created in the mutant transcript because of the usage of the new splice donor
site (underlined). B, Sequences of the wild-type (left) and mutant (right) CHEK2 transcripts (between exons 2 and 3) from the cell line established
from the affected men carrying the IVS21GrA germline mutation. C, Western blot analyses showing the reduction of CHEK2 in the cell lines
carrying the frameshift mutations, compared with the normal lymphocyte cells and the cells carrying CHEK2 missense mutations.
Mutant CHEK2 Altered Protein Expression
The functional importance of the CHEK2 mutations
in prostate cancer development was explored by ex-
amination of the mutant gene products. RT-PCR anal-
ysis of the EBV-transformed cell lines that were estab-
lished from the leukocytes of each proband confirmed
that all CHEK2 mutations were present in their tran-
scripts, including the 1100delC mutation (fig. 1). The
splice-site mutation (IVS21GrA) results in a 4-bp in-
sertion due to an abnormal splicing using an alternative
splice donor site in intron 2 (fig. 3A and 3B). This mu-
tation creates a premature termination codon in exon 3
and eliminates part of FHA domain and the entire kinase
activation domain of CHEK2. Western blot analysis of
the two frameshift mutations in the patients’ cell lines
showed dramatic reduction of CHEK2 protein levels in
both cases (fig. 3C). Reduction of CHEK2 protein has
been shown to reduce the kinase activity of CHEK2 in
response to DNA damage (Matsuoka et al. 2001). Al-
together, our data provide evidence that some of the
CHEK2 mutations identified in the patients with pros-
tate cancer whom we studied lead to disruption of
CHEK2 expression.
Discussion
In the present study, we identified 18 unique germline
CHEK2 mutations among 28 (4.8%) individuals with
prostate cancer and in nine families with familial prostate
cancer. With the exception of two mutations (1100delC
and Ile157Thr) that were previously reported in LFS (Bell
et al. 1999), allCHEK2mutations identified in the present
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study are unique to prostate cancer. Moreover, some of
the mutations presumed to be deleterious are represented
by two new truncation mutations (IVS21GrA and
Glu239Stop), which are predicted to lose their kinase
activities.
Association studies between patients with sporadic
disease and unaffected control individuals indicated an
increased risk of developing prostate cancer in men har-
boring CHEK2 mutations. The risk appears to be higher
when the Ile157Thr mutation is excluded. In contrast,
the frequency of CHEK2 mutations in the familial
group was not significantly different from that in the
control group (table 1). Although the small sample size
may account for this, the finding may reflect the pres-
ence of more-highly-penetrant genes in the familial
group, compared with the other groups. In addition, the
patients having CHEK2 mutations in the familial cases
may themselves represent phenocopies—that is, the
prostate cancer in these patients may be due to CHEK2
mutations and not due to other highly penetrant sus-
ceptibility genes segregating within the family. We rec-
ognize that well-designed epidemiological studies of
large sample sets will be necessary to determine the rel-
evance of these mutations in families with familial pros-
tate cancer.
GermlineCHEK2mutationswere first reported byBell
et al. (1999) in patients with classic LFS and wild-type
p53. LFS is a highly penetrant familial cancer syndrome,
classically associated with germline mutations of TP53.
The spectrum of cancers in this syndrome includes breast
cancer, soft tissue sarcoma, brain tumors, osteosarcoma,
leukemia, and adrenocortical carcinoma (Birch et al.
1984, 1990). Recently, the germline 1100delC mutation
was identified in noncarriers of BRCA1 or BRCA2 mu-
tations from families with breast cancer, the primary can-
cer in LFS (Meijers-Heijboer et al. 2002). This mutation
is thought to confer a low penetrance for breast cancer.
Allinen et al. (2001) screened the CHEK2 gene in 79
Finnish families with hereditary breast cancer that did
not have mutations in BRCA1, BRCA2, or TP53. How-
ever, they found only the Ile157Thr alteration, whichwas
also present in 6.5% of control DNA samples. To date,
other than somatic CHEK2 mutations, there is no germ-
line CHEK2 mutation reported in other primary tumors
of LFS (Miller et al. 2002). It is important to point out
that there was no evidence, on the basis of published
criteria, that the nine families with familial prostate can-
cer in which we detected germline CHEK2 mutations
had LFS or LFL syndrome (Li et al. 1988; Birch et al.
1994). Ascertainment of these families included collec-
tion of family history through telephone interviews and
construction of formal pedigrees.
The most common CHEK2 mutation identified in our
study was Ile157Thr. The role of this mutation, how-
ever, is controversial, even though both genetic and bio-
chemical data from previous studies suggest that this
mutation is deleterious (Bell et al. 1999; Falck et al.
2001; Li et al. 2002). On the other hand, this mutation
was found in 2.1% (2/95) of healthy population control
individuals in Finland and was proposed as a poly-
morphism (Vahteristo et al. 2001). Other reports also
indicate that this mutation is relatively common in nor-
mal healthy control individuals (Allinen et al. 2001;
Meijers-Heijboer et al. 2002). In our current study, the
frequency of this variant was not significantly different
among the several groups of samples tested (1.21% for
the sporadic prostate cancer groups, 2.34% for familial
prostate cancer, 1.18% for unaffected control groups)
(table 1). Whether this functionally related CHEK2 var-
iant confers susceptibility to prostate cancer, or even to
other cancers, remains to be clarified.
The presence of CHEK2 mutations in prostate cancer
highlights the importance of the integrity of the DNA-
damage–signaling pathway in prostate cancer devel-
opment. The fact that mutations in BRCA1 and
BRCA2, two other proteins in this pathway, confer an
increased risk of prostate cancer further supports this
notion (Gayther et al. 2000). Moreover, the recently
developed genomic instability-based transgenic mouse
model for prostate cancer demonstrated the presence of
a similar phenotype of early stages of human prostate
cancer and that the genomic instability could be an early
event in this disease (Voelkel-Johnson et al. 2000).Over-
all, our data provide new genetic evidence for the in-
volvement of the DNA-damage–signaling pathway in
prostate cancer development. Although the mechanism
by which CHEK2 mutations contribute to the devel-
opment of prostate cancer remains unclear, future stud-
ies will add to the observations in the present report.
The finding of germline mutations in CHEK2 in both
sporadic and familial prostate cancer may facilitate
early diagnosis of this cancer and may provide addi-
tional insights into the biology of this malignancy, for
future therapeutic applications.
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